No products in the cart.
Mouse Monoclonal Cyclin D1 antibody [3D8] (STJ97978)
Supplier: St John’s Laboratory Ltd.
Recommended applications: WB, ELISA
Recommended dilution: WB 1:500-1:2000; ELISA 1:10000
Recommended protocols: check protocols
Click or hover above images to see image description for Cyclin D1 Monoclonal Antibody.
Check alternative names for the antibodyExpand
CCND1 antibody, BCL1 antibody, PRAD1 antibody,|AI327039 antibody|B cell CLL/lymphoma 1 antibody|B cell leukemia 1 antibody|B cell lymphoma 1 protein antibody|B-cell lymphoma 1 protein antibody|BCL 1 antibody|BCL-1 antibody|BCL-1 oncogene antibody|BCL1 antibody|BCL1 oncogene antibody|ccnd1 antibody|CCND1/FSTL3 fusion gene, included antibody|CCND1/IGHG1 fusion gene, included antibody|CCND1/IGLC1 fusion gene, included antibody|CCND1/PTH fusion gene, included antibody|CCND1_HUMAN antibody|cD1 antibody|Cyl 1 antibody|D11S287E antibody|G1/S specific cyclin D1 antibody|G1/S-specific cyclin-D1 antibody|Parathyroid adenomatosis 1 antibody|PRAD1 antibody|PRAD1 oncogene antibody|U21B31 antibody|Anti-Cyclin D1 antibody [EPR2241] (ab134175)
SCBT cat No: sc-70899|sc-450|sc-8396|sc-717|sc-56302|sc-20044|sc-753|sc-246|sc-718|sc-452|sc-166288|
Cyclin D1 Monoclonal Antibody
|Catalogue No.|| |
Cyclin D1 Monoclonal Antibody detects endogenous levels of Cyclin D1 protein.
Purified recombinant fragment of human Cyclin D1 expressed in E Coli
|Recommended dilution|| |
WB 1:500-1:2000; ELISA 1:10000
Cyclin D1 Antibody was tube-contained. Ascitic fluid containing 0.03% sodium azide.
Cyclin D1 Antibody was purified using affinity purification.
-20 Celsius degree. Avoid repeated freeze/thaw cycles.
|Alternative antibody names|| |
G1/S-specific cyclin-D1 antibody, B-cell lymphoma 1 protein antibody, BCL-1 antibody, BCL-1 oncogene antibody, PRAD1 oncogene antibody
|Protein names|| |
G1/S-specific cyclin-D1 , B-cell lymphoma 1 protein , BCL-1 , BCL-1 oncogene , PRAD1 oncogene
|Protein function|| |
Regulatory component of the cyclin D1-CDK4 (DC) complex that phosphorylates and inhibits members of the retinoblastoma (RB) protein family including RB1 and regulates the cell-cycle during G1/S transition. Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complex and the subsequent transcription of E2F target genes which are responsible for the progression through the G1 phase. Hypophosphorylates RB1 in early G1 phase. Cyclin D-CDK4 complexes are major integrators of various mitogenenic and antimitogenic signals. Also substrate for SMAD3, phosphorylating SMAD3 in a cell-cycle-dependent manner and repressing its transcriptional activity. Component of the ternary complex, cyclin D1/CDK4/CDKN1B, required for nuclear translocation and activity of the cyclin D-CDK4 complex. Exhibits transcriptional corepressor activity with INSM1 on the NEUROD1 and INS promoters in a cell cycle-independent manner.
|Involvement in disease|| |
Note: A chromosomal aberration involving CCND1 may be a cause of B-lymphocytic malignancy, particularly mantle-cell lymphoma (MCL). Translocation t(11;14)(q13;q32) with immunoglobulin gene regions. Activation of CCND1 may be oncogenic by directly altering progression through the cell cycle.; Note: A chromosomal aberration involving CCND1 may be a cause of parathyroid adenomas. Translocation t(11;11)(q13;p15) with the parathyroid hormone (PTH) enhancer.; Multiple myeloma (MM) [MIM:254500]: A malignant tumor of plasma cells usually arising in the bone marrow and characterized by diffuse involvement of the skeletal system, hyperglobulinemia, Bence-Jones proteinuria and anemia. Complications of multiple myeloma are bone pain, hypercalcemia, renal failure and spinal cord compression. The aberrant antibodies that are produced lead to impaired humoral immunity and patients have a high prevalence of infection. Amyloidosis may develop in some patients. Multiple myeloma is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance (MGUS) to plasma cell leukemia. . Note: The gene represented in this entry is involved in disease pathogenesis. A chromosomal aberration involving CCND1 is found in multiple myeloma. Translocation t(11;14)(q13;q32) with the IgH locus.
|Protein sequence and domain|| |
Belongs to the cyclin family. Cyclin D subfamily. / Contains 1 cyclin N-terminal domain.
|Protein post-translational modifications|| |
Phosphorylation at Thr-286 by MAP kinases is required for ubiquitination and degradation following DNA damage. It probably plays an essential role for recognition by the FBXO31 component of SCF (SKP1-cullin-F-box) protein ligase complex. / Ubiquitinated, primarily as ‘Lys-48’-linked polyubiquitination. Ubiquitinated by a SCF (SKP1-CUL1-F-box protein) ubiquitin-protein ligase complex containing FBXO4 and CRYAB. Following DNA damage it is ubiquitinated by some SCF (SKP1-cullin-F-box) protein ligase complex containing FBXO31. SCF-type ubiquitination is dependent on Thr-286 phosphorylation (By similarity). Ubiquitinated also by UHRF2 apparently in a phosphorylation-independent manner. Ubiquitination leads to its degradation and G1 arrest. Deubiquitinated by USP2; leading to its stabilization.
|Protein cellular localization|| |
Nucleus / Cytoplasm / Membrane
AntibodyPlus can customize Cyclin D1 Antibody according to your requirement, including bulk product size,etc. Please contact email@example.com. AntibodyPlus provide antibody trial sample for your own antibody validation and collects antibody reviews.
St John’s Laboratory Ltd.
|Product type|| |
There are no reviews for this product yet.
By submitting a review, get following benefits:
1. Receive $50 ABcoins as credit for each review.
2. First trial sample order will be fully refunded as credit.
3. Have a chance to win a $50 amazon gift card!
There is no extra validation for this product yet.
Check other extra validated antibodies below: